| Name | Title | Contact Details |
|---|
Founded in 2006 and headquartered near Minneapolis, Minnesota, Respicardia® is dedicated to improving the lives of heart failure patients by developing implantable therapies designed to improve Respiratory Rhythm Management and cardiovascular health. The remedē® System is an innovative implantable stimulation device designed to restore natural breathing during sleep for patients with Central Sleep Apnea.
Precision Optics Corporation has been a developer and manufacturer of advanced optical instruments since 1982. We design and produce high-quality medical instruments, micro optics and assemblies with sizes less than 1 millimeter, and other advanced optical systems. Our medical instrumentation line includes rigid laparoscopes, arthroscopes, sinuscopes, and a line of world-class 3-D endoscopes. We also design and build flexible fiber scopes with diameters as small as 5 microns with illumination for use in minimally invasive surgical procedures. We have a complete line of endocouplers with focal ranges from 20mm - 45mm and a parfocal zoom coupler with focal ranges from 20mm-37mm. We are registered to the ISO 9001:2008, ISO 13485:2003, CMDCAS Quality Standards, and comply with the FDA Good Manufacturing Practices and the European Union Medical Device Directive for CE marking of our medical products.
OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.
Oridion is a Needham Heights, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Our Vision is to make healthcare accessible to patients, without compromise, by delivering the highest quality, fastest, cost effective and portable detection systems that bring the patient and caregiver closer together.